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Abstract 
Background: Rheumatoid arthritis is a chronic inflammatory disease with uncertain etiology. It is characterized 
by symmetric polyarthritis in peripheral joints. Its diagnosis is based on clinical findings and serologic tests. 
However, its diagnosis is rarely conclusive in early course of the disease. So, its early diagnosis could be difficult. 
The present study was designed to evaluate the role of anti -RA33; an auto-antibody against RA33 in early 
diagnosis of the disease. 
Materials and Methods: forty three patients with RA who had been visited in a rheumatology clinic were 
randomly selected. Their disease has been diagnosed by a rheumatologist. They served as the case group. 55 
persons were also chosen from healthy individuals who had attended in other clinic. They served as control. 
Their age and sex were matched with the case group. Anti-RA33 and RF titers were measured in their blood 
sample using standard methods. 
Findings: RF and anti-RA33 titers had significant correlation in the case group (p=0.015). Anti -RA33 test had 
98% sensitivity, 20% specificity, 50% positive predictive value, and 90% negative predictive value. 
Conclusion: Anti -RA33 could have diagnostic and prognostic importance in diagnosis and evaluation of 
patients with RA, and its differentiation from other small joint disorders, particularly when the other serologic 
tests are negative. 
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease with unknown etiology characterized by symmetric 
peripheral polyarthritis. RA is the most common form of chronic inflammatory arthritis. It often results in joint 
damage and physical disability. It is a systemic disease with a variety of extra-articular manifestations including 
fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis, and hematologic 
abnormalities (McInnes & Schett, 2011). 
The incidence of RA rises in ages between 25 and 55 years, and then reaches to plateau until the age 75, and 
afterward decreases. The presenting symptoms of RA typically result from inflammation of the joints, tendons, 
and bursas. The patients often complain from early morning joint stiffness that lasts more than 1 hour and 
improves with physical activity. The small joints of the hands and feet are the earliest involved joints. The initial 
pattern of joint involvement may be mono-articular, oligo-articular (less than 4 joints), or poly-articular (more 
than 5 joints); usually with symmetric distribution (Firth, 2011; Nyhäll-Wåhlin et al., 2011). 
Diagnosis of RA is based on its typical signs and symptoms, with laboratory and radiographic confirmation. In 
2010, a collaborative effort between the American College of Rheumatology (ACR) and the European League 
against Rheumatism (EULAR) leaded to revision of the 1987 ACR classification criteria for diagnosis of RA to 
improve its early diagnosis with the goal of identifying patients who would benefit from early performance of 
disease-modifying therapies (Thabet et al., 2012). However, some patients may remain undiagnosed, do not treat 
at appropriate time to reach the disease remission or low disease activity, and could face with adverse effects of 
more potent therapeutic agents or complications of the disease. Consequently, determination of a more 
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conclusive test for diagnosis of RA is superlative. 
The autoantibody reactivity defined as anti-RA 33 is against a component of the splicosome which is the 
heterogeneous ribonucleoprotein complex 36-kDa A2 protein. The antigen that is associated with mRNA involve 
in regulation of pre- mRNA splicing, mRNA transport and translation .The anti-RA 33 antibodies can be found in 
the tumor necrosis factor-transgenic mice that develop spontaneous arthritis. However, they may contribute in 
pathogenesis of diseases in a nonspecific manner. An exception is auto antibodies against hnRNP-A2, which 
appears to have some relevance with pathogenesis and diagnosis of RA. Hn RNP-A2 is found in skin, lymphoid 
tissues, brain, and reproductive organs with highest expression levels (Conrad et al., 2010). Anti-RA 33 
antibodies occur in approximately one third of patients with RA. Its level remains normally constant in the 
course of the disease (Steiner & Smolen, 2002; Duskin & Eisenberg, 2005). 
Because anti-hnRNPA2 is rarely seen in osteoarthritis, reactive arthritis, ankylosing spondylitis or psoriatic 
arthritis, it can be helpful for differential diagnosis of these diseases with RA, particularly in patients who have 
negative RF and /or ACPA tests. Specificity of Anti-hn RNPA2 antibodies is approximately 90% for RA, which is 
somewhat lower than the specificity of ACPA or Ig M-RF. Similar to RF and ACPA, anti-hnRNP-A2 antibodies 
may appear in the earlier stages of the disease. They do not correlate with Ig M-RF or ACPA and are also not 
associated with radiographic progression of the disease, but rather seem to characterize patients with more 
favorable prognosis (Nell et al., 2005). In some studies, it is reported that anti-RA33 could be seen in 1% of 
normal population. It has also been suggested that it can be measured in early stages of RA (van Boekel et al., 
2002; Fritsch et al., 2002; Mediwake et al., 2001). 
There are not sufficient reports about the value of anti-RA33 in diagnosis of RA. The present study was designed 
to evaluate the role of anti -RA33 in early diagnosis of RA in comparison with RF. 
2. Materials and Methods         
Forty three patients with RA whose disease was diagnosed by a rheumatologist were enrolled in the present study. 
They were randomly selected from a rheumatology OPD clinic in Qazvin city, Iran. They were assigned as case 
group. 55 apparently healthy individuals were also selected from attendants of an OPD clinic. They were 
assigned as control group. Inclusion criterion was RA which had been diagnosed by a rheumatologist. An 
exclusion criterion was suffering from rheumatologic disorders other than RA.  
Details of clinical symptoms, the disease duration, morning stiffness, extra-articular findings, number of the 
affected joints and lab test results have been collected from the patients' medical records. Furthermore, their age, 
gender and the level of education were informed. 
The level of anti -RA33 was compared between the groups. It was measured by ELISA. The cut-off point curve 
of its level was drawn, in which the sensitivity, specificity, and negative and positive predictive values of the test 
have been calculated, as well as its age correlation, and its association with RF. 
The study has been approved by local ethical committee of Qazvin University of Medical Sciences, Iran. All of 
the studied persons provided informed consent for participation in the study. 
3. Results 
The current study was performed on 98 persons included 43 patients and 55 normal subjects, among whom 21 
were male. There was no significant difference between the groups in gender distribution, but in their age, most 
of the subjects in case group were 30–49 years old, and in their level of education, most patients had high school 
education or less, whereas a significant number of subjects in control group had higher education (Table 1). 
In patients group, the mean number of the affected joints was 14.79± 6.33. The mean duration of the disease was 
10.53±10.29 months. The other findings about the case group were shown in Table 2. The RF titer was 
57.16±67.35 in the case group. The mean concentration of anti RA33 was 28.34±16.21 IU/ml. As it has been 
demonstrated in Table 3, there was significant difference between the groups in concentration of RF and anti-RA 
33. 
There was significant and positive relationship between age and RF titer (P=0.001), while there was no 
significant relationship between age and anti-RA33 titer (Table 4). There was also significant and positive 
relationship between RF and Anti RA33 titers (P=0.015). As it can be seen in chart 1, if the cutoff of Anti-RA33 
is set at 11.9, it has 98% sensitivity for recognizing patients with RA. The positive and negative predictive values 
of the test were 50% and 90%, respectively. 
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Table 1. General characteristics of the studied persons in case and control group 





0.805 11 (52.4%) 10 (47.6%) male sex 
44 (57.1%) 33 (42.9%) female 
0.014 13 (65%) 7 (35%) Less than 30 Age (years) 
17 (63%) 10 (37%) 30-39 
13 (56.5%) 10 (43.5%) 40-49 
8 (53.3%) 7 (46.7%) 50-59 





1 (14.3%) 6 (85.7%) No education The level of 
education 9 (31%) 20 (69%) Primary school 
16 (61.5%) 10 (38.5%) High school 
4 (50%) 4 (50%) college 
15 (83.3%) 3 (16.7%) Master of science  
6 (100%) 0 (0%) higher 
 
 
Table 2. the disease characteristics in the case group 
Number (percent)   
42 (97.7) 
 
yes Morning stiffness 
1 (2.3) no 
1 (3.3) Less than 1 Duration of morning stiffness (hour) 
9 (30) 1 
17 (56.7) 1-2 
1 (3.3) 2 
2 (6.6) More than 2 
2 (4.7) yes Extra-articular manifestation 
41 (95.3) no 
 
Table 3. Comparison of RF and anti-RA33 concentrations and age between the studied groups 
P value T Control group Case group  
0.003 3.10 38.45±9.92 47.0±15.60 Age (year) 
0.001 3.45 17.81±38.81 57.16±67.35 RF 
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Table 4. Correlation between RF, anti-RA33 concentrations, and age between the studied groups 
Anti-RA33 RF age  
0.152 ( p value=0.15) 0.329 ( p value less than 0.001)1 age 
0.249 ( p value=0.015) - - RF 
-- - Anti-RA33 
 
Table 5. Sensitivity and specificity of anti RA33 in various cut-off points 
  P value 1- specificity Sensitivity cut-off points 
0.088 0.7620.906 13.8 
0.122 0.7380.868 15.8 
0.166 0.07620.887 14.8 
0.020 0.8330.981 11.9 
  
 
Figure 1. Sensitivity and specificity of anti-RA33 
 
4. Discussion  
In the present study, anti- RA33 concentration was 28.34±16.21 in patients with RA. The test had 98% 
sensitivity for recognizing patients with RA. Its positive and negative predictive values were 50% and 90%, 
respectively. There was significant difference in RF and anti-RA 33 titers between the studied groups.  
Various auto antibodies may appear in the serum of the patients with RA. Some of them are more consistent and 
can be used as conclusive test for diagnosis of the disease, particularly, if they can be measured in the early 
course of the disease (Cordonnier et al., 1996). 
In the study of Fritsch and his coworkers conducted on RA patients, anti-RA33 was positive in 73% of them 
(Fritsch et al., 2002). Its sensitivity and specificity for the disease recognition were 98% and 20% respectively, 
while positive and negative predictive values of the test were 55% and 90%, respectively (Fritsch et al., 2002). In 
another study performed on 10 patients with severe RF, 60% had positive anti-RA33. Among other 40 studied 
patients with non-erosive RA, RF was positive in 18% and anti-RA33 was positive in 60% of them (Chao et al., 
2013). In another study conducted on patients with early RA, 40.8% had positive RF and 28.6% had positive 
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anti-RA33. But, anti-RA33 was positive only 20% in those who had arthritis with unknown cause (Cordonnier et 
al., 1996).In the same study, sensitivity and specificity of the test were 85% and 28.6%, respectively. Its positive 
and negative predictive values were 82.3% and 32.7%, respectively (Cordonnier et al., 1996). 
In the study of Al-Ani in Iraq conducted on 50 patients with established RA, 29 (58%) patients were anti-RA33 
positive and 21(42%) patients were anti-RA33 negative (p<0.05). Sensitivity and specificity of anti-RA33 were 
58% and 92.5%, respectively (Al-Ani, 2013). 
The current study also showed that anti-RA33 test can be used as diagnostic clue for recognition of RA. The 
negative predictive value that attained in the present study, confirms the efficacy of the test in differentiation of 
RA from other similar diseases with small joints involvement. Moreover, as it is stated by other authors, 
anti-Ra33 antibodies are helpful in the diagnosis of RA patients who are anti-ccp and RF negative (Al-Ani, 
2013). 
The present study was performed on patients who were known cases of RA. If we were able to perform it in 
patients with early synovitis, we would be able to compare efficacy of RF and anti-RA33 in early diagnosis of 
RA, because patients with early synovitis who do not have criteria for diseases including RA, infections, 
spondyloarthropathies, and diagnosis must be by exclusion. Some trials revealed that 35-54% of patients did not 
meet for other diseases and were considered as undifferentiated arthritis (van Aken et al., 2003; Hülsemann & 
Zeidler, 1995). At present no standardized definition for early synovitis is accepted. Initial data suggest that the 
percentage of RA diagnosis will increase when the 2010 criteria for RA are applied (van der Linden et al., 2011). 
Therefore, autoantibodies could be helpful to differentiate patients with early synovitis, because autoantibody 
response occurres early during disorders before criteria are completed (Willemze, Ioan-Facsinay, & El-Gabalawy, 
2008). This may be subject of future studies to evaluate effectiveness of the markers in early diagnosis of the 
disease.  
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